- Home
- ABUS vs RGR Comparison
ABUS vs RGR Comparison
Compare ABUS & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- RGR
- Stock Information
- Founded
- ABUS 2005
- RGR 1949
- Country
- ABUS United States
- RGR United States
- Employees
- ABUS N/A
- RGR N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- RGR Ordnance And Accessories
- Sector
- ABUS Health Care
- RGR Industrials
- Exchange
- ABUS Nasdaq
- RGR Nasdaq
- Market Cap
- ABUS 672.1M
- RGR 664.0M
- IPO Year
- ABUS N/A
- RGR N/A
- Fundamental
- Price
- ABUS $3.08
- RGR $36.96
- Analyst Decision
- ABUS Strong Buy
- RGR
- Analyst Count
- ABUS 4
- RGR 0
- Target Price
- ABUS $5.50
- RGR N/A
- AVG Volume (30 Days)
- ABUS 827.5K
- RGR 219.8K
- Earning Date
- ABUS 05-14-2025
- RGR 04-30-2025
- Dividend Yield
- ABUS N/A
- RGR 1.90%
- EPS Growth
- ABUS N/A
- RGR N/A
- EPS
- ABUS N/A
- RGR 1.83
- Revenue
- ABUS $6,403,000.00
- RGR $534,561,000.00
- Revenue This Year
- ABUS $14.57
- RGR N/A
- Revenue Next Year
- ABUS $15.84
- RGR $1.89
- P/E Ratio
- ABUS N/A
- RGR $20.16
- Revenue Growth
- ABUS N/A
- RGR 0.65
- 52 Week Low
- ABUS $2.63
- RGR $34.11
- 52 Week High
- ABUS $4.72
- RGR $47.27
- Technical
- Relative Strength Index (RSI)
- ABUS 39.99
- RGR 48.65
- Support Level
- ABUS $2.94
- RGR $32.74
- Resistance Level
- ABUS $3.42
- RGR $37.24
- Average True Range (ATR)
- ABUS 0.18
- RGR 1.25
- MACD
- ABUS -0.04
- RGR 0.15
- Stochastic Oscillator
- ABUS 17.72
- RGR 51.65
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.